We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amends to Agreement with Microsaic Systems; RPT

13 Dec 2021 07:00

RNS Number : 3553V
Deepverge PLC
13 December 2021
 

13 December 2021

 

DeepVerge PLC

("DeepVerge" or "Company")

 

Modern Water Mobile Services pandemic response detection to include mass spectrometry as part of DeepVerge and Microsaic Systems plc Technology and Commercial Agreement

 

 

DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces that it is expanding the range of dangerous pathogens to be detected within Modern Water Mobile Services ("MWMS") with additional product purchases under the Company's existing Technology and Commercial Agreement (the "Agreement") with Microsaic Systems plc ("Microsaic"), details of which were notified in the RNS of 24 March 2021.

 

It is also amending the terms of the Agreement to allow provision of additional goods and services, including those which may be developed in the future by Microsaic.

 

Miniaturised compact technology of Microtox® PD and mass spectrometry

 

The initial roll out of Modern Water Mobile Services will include modified miniaturised mass spectrometry equipment and services supplied by Microsaic. The value of the current purchase is approximately £262k. This order includes some newly developed products - Microsaic's solid phase extraction - liquid chromatography ("SPE-LC") System - and related consumables with a total value of c.£153k which are currently not covered under the Agreement. These will be used for quality and contamination detection in a range of markets including water and soil analysis.

 

The SPE-LC System is expected to be used to detect contaminants of emerging concern and will form part of DeepVerge's third generation solution of multiplex pathogen detection and the launch of its Modern Water Mobile Services, which will facilitate auto-sampling at wastewater sites to reduce the time and cost of detection.

 

Gerard Brandon, CEO of DeepVerge plc (and ecowaterOS member), commented:

 

"We are delighted to have worked over many months with the amazing team at Microsaic, transitioning equipment designed to operate in laboratories, modified to function as road-worthy mobile real-time detection equipment. Calling on the 20 years of expertise in electronic miniaturisation at Microsaic and 34 years detection of dangerous pathogens in Modern Water to deliver state-of-the-art, third generation, pandemic response detection units in such a short period of time, by altering and miniaturising existing equipment from both companies."

 

Related Party Transactions

 

As set out above, an order for £262k has been placed which includes new products and related consumables to the value of £153k which fall outside the scope of the existing Agreement.

 

It is proposed to amend the Agreement such that the provision of the new SPE-LC System, and additional goods and services which Microsaic may develop and supply in future can be supplied to the Company in line with the current terms of the Agreement. Any such amendments to the Agreement will necessarily be made subject to the mutual consent of DeepVerge and Microsaic and include provision requiring each party to consult with its respective nominated adviser on any proposed additional goods to be added to the Agreement from time to time.

 

The purchase of the new products and related consumables outside the scope of the Agreement constitutes a related party transaction for the Company under AIM Rule 13, as DeepVerge directors Gerard Brandon (CEO) and Nigel Burton (Non-executive Director) are also non-executive directors of Microsaic.

 

The Directors of DeepVerge (excepting Messrs Brandon and Burton) consider, having consulted with SPARK Advisory Partners Limited, the Company's nominated adviser, that (i) the terms of the purchase of the additional products and consumables are consistent with both the terms of the Agreement and previous orders under the Agreement, and consider the terms of the purchase of the additional product and consumables to be fair and reasonable insofar as shareholders are concerned and (ii) the amendment to the terms of the Agreement to be fair and reasonable insofar as shareholders are concerned.

 

DeepVerge plc

Ross Andrews

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments and the data they generate, for the analysis and identification of bacteria, virus and toxins. DeepVerge is utilising artificial intelligent data analytics to prove scientifically the impact of skincare product claims on the skin microbiome for clients including most of the top 20 global cosmetic companies and to detect remotely, and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

 

About Microsaic (www.microsaic.com)

 

Microsaic listed on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested £30m over the last 20 years before and after the IPO, Microsaic has a robust patent portfolio in cutting-edge technology purpose built for "Industry 4.0" which enables analytical detection and characterisation at the point-of-need, whether within a human health environment, conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection and monitoring of data at any step in the process workflow.

 

Microsaic's products and systems are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing, and point-of-need applications. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRTTBATMTMBBLB
Date   Source Headline
27th Dec 20237:00 amRNSCancellation - DEEPVERGE PLC
20th Dec 202312:30 pmRNSUpdate; exclusivity agreement with Microsaic
13th Dec 20234:38 pmRNSUpdate
14th Sep 20237:00 amRNSNew Website, Update
7th Aug 20232:30 pmRNSDisposal;Update; Related Party Trans'n-replacement
7th Aug 20237:00 amRNSDisposal; Update
2nd Aug 20239:35 amRNSBoard Change
1st Aug 20237:00 amRNSCompany Secretary Change
12th Jul 20237:00 amRNSUpdate
5th Jul 202311:26 amRNSUpdate
26th Jun 20237:30 amRNSSuspension - Deepverge PLC
26th Jun 20237:00 amRNSSale or closure of subsidiaries; share suspension
5th Jun 20237:00 amRNSCost reductions;delay to Ann. Report;New contract
19th Apr 20231:21 pmRNSMicrosaic Creditor; Update
17th Apr 20237:00 amRNS2022 revenue update - revision
24th Mar 202310:24 amRNSChange of Auditor
6th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20232:05 pmRNSSecond Price Monitoring Extn
6th Mar 20232:00 pmRNSPrice Monitoring Extension
22nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20234:35 pmRNSPrice Monitoring Extension
7th Feb 20237:00 amRNSBoard Appointment
6th Feb 20235:30 pmRNSSignificant contract win and Board change
2nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
2nd Feb 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20237:00 amRNS2022 Revenue Update
23rd Nov 20224:10 pmRNSTR-1: Notification of major holdings
22nd Nov 20227:00 amRNSAccelerated Restructuring
16th Nov 20229:00 amRNSDirector/PDMR Shareholding
14th Nov 202212:16 pmRNSResult of Meeting
11th Nov 20224:37 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirectorate and Management Changes
3rd Nov 202212:32 pmRNSDirectorate Change
1st Nov 20223:56 pmRNSResult of Broker Offer; Total Voting Rights
31st Oct 20222:23 pmRNSBroker Offer to raise a max of £2.5m - replacement
31st Oct 20222:18 pmRNSExtension of Broker Offer to 430pm on 31 October
28th Oct 20221:06 pmRNSExtension of Broker Offer
27th Oct 20227:01 amRNSBroker Offer to raise a maximum of £2.5m
27th Oct 20227:00 amRNS£10m Placing, Broker Option, RPTs, Notice of GM
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 20227:01 amRNSUpdate - Proposed Financing,Proposed Board Changes
25th Oct 20227:00 amRNSHistorical Related Party Transactions
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:04 amRNSResponse to Market Speculation
11th Oct 202211:05 amRNSSecond Price Monitoring Extn
11th Oct 202211:00 amRNSPrice Monitoring Extension
4th Oct 20227:00 amRNSLabskin contract
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.